Listen to “THE FIRST MAJOR DEVELOPMENT IN 20 YEARS TO HELP MANAGE CHRONIC KIDNEY DISEASE IN PATIENTS RISK OF PROGRESSION WITH & WITHOUT TYPE 2 DIABETES” on Spreaker.
Chronic kidney disease (CKD) is a life-threatening disease that is vastly underdiagnosed and affects an estimated 37 million, or 1 in 7, American adults.[1][2] With limited treatment options available, a new therapy is critical for people living with CKD to help slow disease progression – which is why the recent FDA approval of a new therapy to treat CKD in patients at risk of progression with and without type 2 diabetes (T2D) is monumental for this patient population.
CKD is a progressive condition and patients with CKD have an increased risk of having heart disease.[1][3] However, most patients don’t know they have CKD, in large part because it is a “silent” disease, with most patients feeling no symptoms until the disease has progressed.[4] In fact, while approximately 15% of US adults are living with CKD, 9 in 10 are unaware they have CKD.[1]
Now, a new treatment option has been proven to help slow the progression of CKD – a huge scientific innovation for CKD patients at risk of progression with and without T2D. This approval is the most significant advancement in the treatment of CKD in over 20 years.
Because CKD may be overlooked until symptoms appear at advanced stages, it is especially important to be aware of risk factors and the serious complications that can occur.[1][5]
CKD tends to get worse over time, so the earlier treatment starts, the better the patient outcomes are. [3]
On May 19, Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College of Thomas Jefferson University, will be available to discuss the latest treatment option approved by the FDA. Dr. Skolnik will also discuss risk factors and the importance of early detection of CKD.
Interview Courtesy: AstraZeneca
1. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html.
2. AstraZeneca. Diagnose CKD Now. https://www.diagnoseckdnow.com/
3. Centers for Disease Control and Prevention. Chronic Kidney Disease Basics. www.cdc.gov/kidneydisease/basics.html.
4. National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease Statistics for the United States. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease.
5. National Kidney Foundation. Estimated Glomerular Filtration Rate (Egfr). https://www.kidney.org/content/gfr]
#astrazeneca #farxiga #kidney #disease #health #chronic #patient #risk #diabetes #treatment #therapy #heart #ckd #neil #skolnik #thomas #jefferson #medicine #medical #family #factors
HUGO BOSS Fashions & Samuel Waxman Cancer Research Foundation Announce Launch of Global Walk to Flatten the Cancer Curve